Biosphere tenant Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression.

Iksuda Therapeutics (Iksuda), a developer of next generation Antibody Drug Conjugates (ADCs), today announced it will present the first data on its lead ADC, IKS01, at ESMO Congress 2019. [...]

By |2019-09-30T15:07:04+00:00September 30th, 2019|News|0 Comments
Load More Posts